User: TahirAmin Topic: IP
Category: patent-legal-regime :: india
Last updated: Sep 19 2014 23:55 IST RSS 2.0
 
1 to 20 of 2,591    
‘PM Modi must firmly rebuff US pressure to dilute India’s robust patent law’ 19.9.2014 HBL: Features
Concessions will disarm India in its pursuit of the right to health
Also found in: [+]
We need an ecosystem of innovation to retain our young scientists: Novartis India chief 19.9.2014 HBL: Companies
MNCs overseas hire 15% of their research hands from India
Also found in: [+]
Hepatitis C drug in India to cost 49 lakh less than in US 16.9.2014 ET: Pharma
The voluntary licencing deal promises to make the drug cheap in India as well as up to 91 countries where the Indian firms are allowed to sell it.
Also found in: [+]
Pill for thought: Sweetheart deals that hurt consumers 16.9.2014 Rediff: Top Stories (India)
'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators
Also found in: [+]
Hepatitis C drug in India to cost 49 lakh less than in US 16.9.2014 TOI: India
Sofosbuvir, the wonder medicine for Hepatitis C that costs $84,000 or Rs 50.4 lakh for a 24-week treatment regimen in the US, will soon be available in India for about $1,800 or roughly Rs 1.1 lakh for the same ...
Also found in: [+]
Vaibhav Choukse: Sweetheart deals that hurt consumers 15.9.2014 Columns
'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators
Also found in: [+]
Judiciary's independence is non-negotiable: CJI RM Lodha - Firstpost 14.9.2014
Judiciary's independence is non-negotiable: CJI RM Lodha Firstpost New Delhi: Chief Justice of India RM Lodha today asserted that independence of judiciary is "non-negotiable" and it has the inherent strength to foil any attempt to interfere with that. In remarks that come against the backdrop of steps to end the ...
Also found in: [+]
Pfizer, Ranbaxy win lawsuit over generic Lipitor 13.9.2014 deccanherald.com
Pfizer Inc and Indias Ranbaxy Laboratories Ltd won dismissal of a U.S. antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the best-selling cholesterol drug Lipitor. US District Judge Peter Sheridan in Trenton, New Jersey, ruled that the plaintiffs, retailers and distribution companies that bought Lipitor directly from Pfizer, failed to plead their case with enough detail. The lawsuit, filed in 2012, stems from a 2008 settlement of a patent lawsuit filed by Pfizer against Ranbaxy over Ranbaxys plan to make generic Lipitor. Under the deal, Pfizer agreed to drop a claim for damages against Ranbaxy, and Ranbaxy agreed to stay out of the Lipitor market until November 2011. Retailers and distribution companies claim that the settlement amounted to Pfizer paying Ranbaxy to stay out of the Lipitor market, violating antitrust laws. But Sheridan ruled on Friday that their case failed because they did not offer any allegation of the settlements dollar value. Sheridan dismissed ...
Also found in: [+]
Judiciary’s independence is non-negotiable: CJI RM Lodha 13.9.2014 FirstPost: India

The CJI called upon the legal fraternity to keep away people who "play tricks to taint judiciary" saying any form of corruption in judiciary "shield impurity which is the worst form of aliment in thriving democracy."

The post Judiciary’s independence is non-negotiable: CJI RM Lodha appeared first on Firstpost.

Also found in: [+]
Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor 13.9.2014 Sify Finance
Also found in: [+]
Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor 13.9.2014 Asian Age: Business
The 2012 lawsuit stems from a 2008 settlement of a patent lawsuit filed by Pfizer Pfizer Inc and India's Ranbaxy Laboratories Ltd on Friday won dismissal of a US antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the best-selling cholesterol drug Lipitor. US District Judge Peter Sheridan in Trenton, New Jersey, ruled that the plaintiffs, retailers and distribution companies that bought Lipitor directly from Pfizer, failed to plead their case with enough detail. The lawsuit, filed in 2012, stems from a 2008 settlement of a patent lawsuit filed by Pfizer against Ranbaxy over Ranbaxy's plan to make generic Lipitor. Under the deal, Pfizer agreed to drop a claim for damages against Ranbaxy, and Ranbaxy agreed to stay out of the Lipitor market until November 2011. Retailers and distribution companies claim that the settlement amounted to Pfizer paying Ranbaxy to stay out of the Lipitor market, violating antitrust laws. But Sheridan ruled Friday that their case failed because ...
Also found in: [+]
Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor 13.9.2014 TOI: All Headlines
Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor
Also found in: [+]
US drug patent expiries to benefit Indian pharma industry 10.9.2014 DNA: Popular News
Expiry of drug patents in the US is great news for not only consumers but also the domestic pharmaceutical industry, where generics account for about 75 per cent of total sales, CARE Ratings said in its report released here today. Indian pharmaceutical companies have an opportunity to capitalise on the patent cliff and gain a greater share of the growing generics market. At present, India accounts for nearly 40 per cent of generic drugs, over-the-counter products and 10 per cent of finished dosages used in the US. During 2014-2016, about USD 92 billion worth of patented drugs are expected to go off-patent in the USA as compared to USD 65 billion during 2010-12. Indian companies' share in the US generics market has grown rapidly on the back of aggressive Abbreviated New Drug Application (ANDA) filings, successful pursuit of Para-IV and capitalisation on patent expiries of blockbuster drugs. Under US laws, ANDA filed with a Para-IV certification states that the generic company which is the first-to-file a ...
Also found in: [+]
US drug patent expiries to benefit Indian pharma industry 10.9.2014 CNN-IBN: World
Expiry of drug patents in the US is great news for not only consumers but also the domestic pharmaceutical industry, where generics account for about 75 per cent of total sales, CARE Ratings said in its report released on Wednesday.
Also found in: [+]
Govt to Come Out with IPR Policy in 6 mths 9.9.2014 newindianexpress.com
Such a policy will give more teeth to the intellectual property rights regime besides providing clarity and protection to the industry
Also found in: [+]
IPR policy on the cards to protect national interests, says Nirmala Sitharaman 9.9.2014 ET: Policy
The US is threatening to downgrade India’s intellectual property environment in an out-of-cycle review expected shortly.
Also found in: [+]
IPR policy in the works 9.9.2014 Telegraph: Business
New Delhi, Sept. 8: The government plans to come out with a policy on intellectual property rights (IPR) within a few months, with developed nations such as the US and the EU raising concerns over the country's patent rules.
Also found in: [+]
Ahead of Modi's US visit: Govt says will hammer out IPR policy 9.9.2014 All Economy & Policy Stories
To give more teeth to patents regime
Also found in: [+]
India will soon have a new IPR policy, says Sitharaman 8.9.2014 Deccan Herald - Business
In a few months from now, India will have a new policy on Intellectual Property (IP) regime in place to give more protection to domestic industry. The government will also set up a think tank to deal with IPR issues with a firm handle. "India does not have an IPR policy. This is the first time we are coming out with an IPR policy. IPR policy issues have been hanging for quite a long time," Commerce and Industry Minister Nirmala Sitharaman told reporters. "It will give direction in terms of protecting IPR of India on which several issues are there. With the US we have (certain) issues... India has become a brand in terms of pharma... We are very strong in IPR and we certainly want to protect our interest,"she said. The United States and European Union have been strongly criticising India's investment climate and IPR laws, especially in the pharmaceuticals and the solar sectors. The Minister, however, did not clarify whether the concerns raised by the US and the EU on certain provisions of the Indian ...
Also found in: [+]
Centre working on a new IP policy 8.9.2014 HBL: Companies
BJP still opposed to FDI in multi-brand retail, but won’t scrap existing rules: Minister
Also found in: [+]
1 to 20 of 2,591